BNP Paribas Financial Markets Purchases 24,621 Shares of DaVita Inc. $DVA

BNP Paribas Financial Markets grew its holdings in shares of DaVita Inc. (NYSE:DVA) by 25.4% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 121,447 shares of the company’s stock after buying an additional 24,621 shares during the period. BNP Paribas Financial Markets’ holdings in DaVita were worth $13,798,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the business. Todd Asset Management LLC bought a new stake in shares of DaVita during the third quarter worth $21,842,000. Doma Perpetual Capital Management LLC lifted its position in shares of DaVita by 23.3% during the third quarter. Doma Perpetual Capital Management LLC now owns 355,574 shares of the company’s stock worth $47,245,000 after purchasing an additional 67,214 shares during the last quarter. Intech Investment Management LLC lifted its position in shares of DaVita by 122.4% during the third quarter. Intech Investment Management LLC now owns 27,441 shares of the company’s stock worth $3,646,000 after purchasing an additional 15,104 shares during the last quarter. Nordea Investment Management AB lifted its position in shares of DaVita by 18.0% during the fourth quarter. Nordea Investment Management AB now owns 338,192 shares of the company’s stock worth $38,321,000 after purchasing an additional 51,607 shares during the last quarter. Finally, Munich Reinsurance Co Stock Corp in Munich bought a new stake in shares of DaVita during the third quarter worth $5,419,000. 90.12% of the stock is currently owned by institutional investors.

Insider Transactions at DaVita

In other DaVita news, CFO Joel Ackerman sold 51,471 shares of DaVita stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $192.10, for a total value of $9,887,579.10. Following the transaction, the chief financial officer owned 132,434 shares in the company, valued at $25,440,571.40. The trade was a 27.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.50% of the stock is owned by company insiders.

DaVita Price Performance

DVA stock opened at $192.28 on Monday. The business has a 50-day moving average price of $171.47 and a 200 day moving average price of $143.36. The company has a market capitalization of $12.34 billion, a P/E ratio of 17.84, a PEG ratio of 0.63 and a beta of 0.91. DaVita Inc. has a 1-year low of $101.00 and a 1-year high of $202.69.

DaVita (NYSE:DVA) last released its quarterly earnings data on Tuesday, May 5th. The company reported $2.87 earnings per share for the quarter, beating the consensus estimate of $2.33 by $0.54. The firm had revenue of $3.42 billion during the quarter, compared to the consensus estimate of $3.36 billion. DaVita had a negative return on equity of 270.37% and a net margin of 5.65%.The firm’s quarterly revenue was up 6.0% on a year-over-year basis. During the same period in the previous year, the company posted $2.00 earnings per share. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, analysts anticipate that DaVita Inc. will post 15.07 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on DVA shares. Deutsche Bank Aktiengesellschaft upgraded DaVita from a “hold” rating to a “buy” rating and lifted their target price for the stock from $126.00 to $220.00 in a research report on Wednesday, May 6th. UBS Group lifted their target price on DaVita from $190.00 to $235.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Barclays lifted their price objective on DaVita from $158.00 to $194.00 and gave the company an “equal weight” rating in a report on Thursday, May 7th. TD Cowen lifted their price objective on DaVita from $144.00 to $201.00 and gave the company a “hold” rating in a report on Monday, May 11th. Finally, Truist Financial lifted their price objective on DaVita from $158.00 to $205.00 and gave the company a “hold” rating in a report on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $199.17.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.